Vical Incorporated (VICL) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $12. H.C. Wainwright advised their investors in a research report released on Jul 19, 2016.
On the company’s financial health, Vical Incorporated reported $-0.03 EPS for the quarter, based on the information available during the earnings call on Mar 14, 2016. Analyst had a consensus estimate of $-0.03. The company had revenue of $6.48 million for the quarter, compared to analysts expectations of $5.07 million. The company’s revenue was up 53.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.
Vical Incorporated closed down -0.03 points or -0.68% at $4.36 with 8,734 shares getting traded on Monday. Post opening the session at $4.37, the shares hit an intraday low of $4.3376 and an intraday high of $4.47 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jul 13, 2016, Lawrence Russell Smith (VP, Vaccine Research) sold 54 shares at $4.46 per share price. According to the SEC, on Jun 14, 2016, Robert C Merton (director) purchased 9,000 shares at $4.35 per share price. On Jun 10, 2016, Vijay B Samant (CEO) purchased 15,700 shares at $4.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent or partnered development programs in the areas of infectious disease consisted of: Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2) a cause of recurrent genital herpes and a completed preclinical program with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.